A QD Clinic: #RA - GI Fast Track Seronegative RA with GI Complaints - who should manage this patient? RA QD Clinics are video vignettes with lessons from the clinic. RA QD Clinics and the "Hard Decisions in RA" September Campaign is sponsored by BMS. https://t.co/t5s3diKGYK https://t.co/bhdCgNpBw2

A new download! ALL the TNR Survey Slides - Hard Decisions in #RA ' https://t.co/cjLigji9I5 https://t.co/itElAVu9ng

Focus on the Fasting Lipid Profile There has been much discussion of late regarding the important topic of how best to manage the independent cardiovascular risk associated with rheumatoid arthritis and other rheumatic diseases. #RA https://t.co/6Ed4vLMj5d https://t.co/oRRvnIWmuZ

This Tuesday Night Rheumatology panel discusses "DMARD Choices & Changes", including weaning, biosimilars, and guideline views from a panel that includes Drs. Madelaine Feldman, Alan Matsumoto, Artie Kavanaugh and Jack Cush. #RA https://t.co/zqe0kOM62X https://t.co/lvfNtANx15

Uncertainty on Pre-Clinical #RA – Rheumatologist Survey Results In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice. https://t.co/khPJMuItDB https://t.co/qhtQ8mAKOI

PBMC RNA-seq studies of Still's pts finds those with #MAS express type I interferon (IFN-I) genes w/ expected IFN-γ signal, coming from cycling CD38+HLA-DR+ cells within CD4+ T cell, CD8+ T cell and NK cell populations. (Synergy w/ IL-15?) https://t.co/QloprexevT https://t.co/JZH2lzZ8rs

Study of 138 #AOSD (Stills) pts - 19% were obese BMI>30. Obese with AOSD have same clinical features as others, but may have higher ferritin & CRP (correl w/ BMI) and more likely to have chronic disease course and bDMARD failure. https://t.co/16wKVGTWnN https://t.co/daR9hZpA89

The Future of #RA Dr. Iain McInnes, Glasgow and Dr. Gerd Burmester, Berlin, discuss their perspectives on the future management of people with rheumatoid arthritis, as part of RheumNow's Hard Decisions in RA campaign. https://t.co/Lkc7bm8SNy https://t.co/RZUylzlEna

FDA has approved palovarotene (Sohonos) as 1st Rx for fibrodysplasia ossifcans progressiva (FOP), a severely disabling condition that causes abnormal bone formation in place of soft and connective tissues. https://t.co/oiPMIDzqYP https://t.co/7rfozgPM9I https://t.co/V2w1X137Xa

Painful Truth of #Gout - affects 2–4% adults in USA, UK, & Europe; >10% Asia-Pacific pts. The global burden of gout is increasing. - Majority of pts not on ULT - Majority not T2T monitored - health literacy on gout is vital https://t.co/ypomR2hhFX https://t.co/JPLLUPJkOE

FDA has approved subcutaneous (SC) vedolizumab (Entyvio) for maintenance in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with intravenous vedolizumab https://t.co/0RD2TW1HgL https://t.co/q9IfbCee3U

Int'l cohort study of 431 established #PSA pts shows PsA patients w/ comorbid obesity were 2.5–3 folds less likely in remission/LDA (ORs 0.31, 0.39) vs non-obese. Obese PsA were more women, w/ higher TJC, pain, enthesitis counts & worse QOL https://t.co/OU1D14vLwv https://t.co/IhUDUd5MNv